Recent blog posts
Mozart Therapeutics Begins Phase 1 Trial of MTX-101 for Autoimmune Treatment
Latest Hotspot
3 min read
Mozart Therapeutics Begins Phase 1 Trial of MTX-101 for Autoimmune Treatment
21 June 2024
Mozart Therapeutics Administers Initial Dose in Phase 1 Clinical Study of MTX-101 for Autoimmune Disease Therapy.
Read →
FDA Approves Zymeworks' ZW171, a New Bispecific Antibody for Mesothelin-related Tumors
Latest Hotspot
3 min read
FDA Approves Zymeworks' ZW171, a New Bispecific Antibody for Mesothelin-related Tumors
21 June 2024
Zymeworks Receives FDA Approval for ZW171, a New Bispecific Antibody Targeting Mesothelin-related Tumors.
Read →
iTeos and GSK Initiate Phase 3 GALAXIES Lung-301 Trial for Advanced Lung Cancer Treatment
Latest Hotspot
3 min read
iTeos and GSK Initiate Phase 3 GALAXIES Lung-301 Trial for Advanced Lung Cancer Treatment
21 June 2024
iTeos and GSK Launch Phase 3 GALAXIES Lung-301 Trial, Evaluating Belrestotug and Dostarlimab in Untreated, Inoperable Advanced/Metastatic PD-L1 Positive Non-Small Cell Lung Cancer.
Read →
Kira Pharmaceuticals Presents Positive KP104 Phase 2 PNH Results at 2024 EHA Congress: Safety and Effectiveness
Latest Hotspot
3 min read
Kira Pharmaceuticals Presents Positive KP104 Phase 2 PNH Results at 2024 EHA Congress: Safety and Effectiveness
21 June 2024
Kira Pharmaceuticals Shares Encouraging KP104 Phase 2 PNH Trial Outcomes at 2024 EHA Congress, Highlighting Sustained Safety and Effectiveness.
Read →
Subcutaneous Amivantamab BLA Submitted to U.S. FDA for EGFR-Mutant Non-Small Cell Lung Cancer
Latest Hotspot
3 min read
Subcutaneous Amivantamab BLA Submitted to U.S. FDA for EGFR-Mutant Non-Small Cell Lung Cancer
21 June 2024
A Biologics License Application for subcutaneous amivantamab was submitted to the U.S. FDA for people with non-small cell lung cancer with EGFR mutations.
Read →
Takeda Releases Phase 3 Topline Data for Soticlestat (TAK-935) in Dravet and Lennox-Gastaut Syndromes
Latest Hotspot
3 min read
Takeda Releases Phase 3 Topline Data for Soticlestat (TAK-935) in Dravet and Lennox-Gastaut Syndromes
19 June 2024
The SKYLINE trial was a multicenter, randomized, and double-blind Phase 3 study that assessed the combination of soticlestat (TAK-935) with standard care against a placebo with standard care in patients suffering from refractory Dravet syndrome.
Read →
Nurix Therapeutics Announces Positive NX-5948 Trial Results in CLL Patients at EHA2024
Latest Hotspot
3 min read
Nurix Therapeutics Announces Positive NX-5948 Trial Results in CLL Patients at EHA2024
19 June 2024
Nurix Therapeutics Reports Successful Outcomes from NX-5948 Trial in Relapsed Refractory CLL Patients at EHA2024 Congress.
Read →
Electra Therapeutics Unveils Phase 1b Trial Results of ELA026 for sHLH at EHA2024
Latest Hotspot
3 min read
Electra Therapeutics Unveils Phase 1b Trial Results of ELA026 for sHLH at EHA2024
19 June 2024
Electra Therapeutics Reveals New Clinical Findings at EHA2024 from Active Phase 1b Trial of ELA026 for Secondary Hemophagocytic Lymphohistiocytosis (sHLH).
Read →
Cabaletta Bio Announces Positive Early Results for CABA-201 Phase 1/2 Studies in Myositis and SLE
Latest Hotspot
3 min read
Cabaletta Bio Announces Positive Early Results for CABA-201 Phase 1/2 Studies in Myositis and SLE
19 June 2024
Cabaletta Bio Releases Favorable Early Clinical Results from Phase 1/2 RESET-Myositis™ and RESET-SLE™ Studies of CABA-201.
Read →
Kymera Therapeutics Reveals New Phase 1 Trial Data for KT-333 at EHA Event
Latest Hotspot
3 min read
Kymera Therapeutics Reveals New Phase 1 Trial Data for KT-333 at EHA Event
19 June 2024
Kymera Therapeutics Unveils Fresh Clinical Data from Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Event.
Read →
Galapagos Reveals Promising CD19 CAR-T Therapy Results for Non-Hodgkin Lymphoma at EHA 2024
Latest Hotspot
3 min read
Galapagos Reveals Promising CD19 CAR-T Therapy Results for Non-Hodgkin Lymphoma at EHA 2024
19 June 2024
Galapagos unveils promising new results for CD19 CAR-T therapy GLPG5101 in non-Hodgkin lymphoma at EHA 2024.
Read →
FDA Approves Blincyto for CD19-Positive Philadelphia Chromosome-Negative B-ALL in Consolidation Stage
Latest Hotspot
3 min read
FDA Approves Blincyto for CD19-Positive Philadelphia Chromosome-Negative B-ALL in Consolidation Stage
18 June 2024
FDA authorizes Blincyto® (blinatumomab) for CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (B-ALL) during consolidation stage.
Read →